Three things to fill in:
Two examples run throughout: a speciality coatings manufacturer chasing a failure mechanism (science), and a regional craft brewery going national (strategy).
Only the pain point — the raw problem as you experience it, in plain language.
Our flagship marine anti-corrosion coating is failing early on offshore wind monopiles: field inspections show blistering and under-film corrosion at 3–5 years against a 15-year specification. Warranty claims are rising, two certification bodies have opened reviews, and our largest OEM customer has qualified a competitor’s product for its next tender round. Our internal team has eliminated the obvious causes — application error, batch variation — without finding the mechanism.
We’ve had five years of steady growth in the North West but our national retail listings have plateaued. Tesco and Sainsbury’s have refused range extensions three times. Our direct-to-consumer subscriber base has stopped growing. Meanwhile, two well-funded London competitors have secured national listings on their first attempt, and one has just been acquired by a major brewer. We’re at risk of being locked out of the mass-market shelf before we finish scaling production.
Only the desired ideal outcome — what “solved” looks like.
Identify the single most likely failure mechanism — one candidate mechanism, stated causally and falsifiably — that explains early blistering and under-film corrosion on submerged and splash-zone steel, and that our laboratory can test within one quarter. We operate a full coatings lab (salt-spray, EIS, cyclic ageing, adhesion), hold ten years of batch records, and retain failed panels from six sites.
Reach £50M annual revenue by end of 2028, with at least 40% coming from customers outside the North West. We have a 120-strong team, a fully-owned production facility with 30% spare capacity, and an established direct-to-consumer platform with 45,000 active subscribers.
Minimums a solution must clear — “at least X” statements.
Any candidate mechanism must be testable on our existing laboratory equipment within 12 weeks. It must be consistent with all six documented site failures. Any reformulation direction must keep salt-spray endurance at or above 1,440 hours.
Product margin at or above 32% on every SKU. Retention at or above 70% for direct-to-consumer subscribers year-over-year. Any new production line must clear the same environmental audit as our current facility.
Maximums a solution must stay under — “at most X” statements.
First-year validation budget capped at £150k. No candidate may require panel ageing longer than six months before a decisive read-out. Reformulation directions must keep raw-material cost within 110% of the current formulation.
Total capital spend on the growth plan under £15M cumulative through 2028. Headcount growth capped at 40% relative to the current 120. Any new geography must reach contribution-positive within 18 months of launch.
Categorical prohibitions — “not X”, regardless of upside.
No mechanisms that presuppose application error — that route is exhausted. No reformulation directions using substance classes on the REACH authorisation candidate list. No solutions requiring capital equipment we do not own. No engagement of the certification bodies before internal validation completes.
No white-label contract brewing for other brands. No sale of a controlling stake to a strategic acquirer during the plan period. No relocation of headquarters out of the North West. No products outside the beer and low-alcohol adjacencies.
Named exceptions to the Walls above — permitted only under stated conditions.
A REACH candidate-list substance IS permitted for diagnostic experiments only, subject to never entering a commercial formulation direction. External test-house capacity IS permitted for one accelerated-ageing protocol, subject to total cost remaining under the £150k Ceiling.
White-label contract brewing IS permitted for a single lighthouse retailer (Waitrose only), subject to margin remaining above the 32% Floor. A minority equity stake to a strategic partner IS permitted up to 25% of the cap table, subject to no board control transferred. Launch of a non-beer product IS permitted for one soft-drink adjacency, subject to it using existing distribution infrastructure.
Soft leanings — “ideally”, “prefer”, “where possible”.
Prefer mechanisms that also explain why failures cluster in the splash zone. All else equal, prefer reformulation directions compatible with our existing application process.
Prefer growth that keeps production in-house rather than licensed. Where two routes are otherwise equal, prefer the one that strengthens the direct-to-consumer subscriber base.